Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-Cause mortality in patients with Type 2 Diabetes (ZODIAC-30)

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 839-845

  Landman, Gijs W D ^a   Van Dijk, Peter R ^a   Drion, Iefke ^a   Van Hateren, Kornelis J J ^a   Struck, Joachim ^b   Groenier, Klaas H ^c   Gans, Rijk O B ^c   Bilo, Henk J G ^a,c   Bakker, Stephan J L ^c   Kleefstra, Nanne ^a,c,d  

^a ISALA HOSPITAL   (Netherlands)

^b ADRENOMED AG   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; PROADRENOMEDULLIN; ADRENOMEDULLIN; BIOLOGICAL MARKERS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

ADULT; AGE; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DISEASE DURATION; GENDER; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; PHYSIOLOGY; PROGNOSIS; RISK FACTORS;

ADRENOMEDULLIN; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; RISK FACTORS;

EID: 84896703444     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1852     Document Type: Article

References (32)

1. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011;34(Suppl. 2):S285-S290
2. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994;338:6-10
3. Samson WK. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 1999;61: 363-389
4. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem 1998; 44:571-577
5. Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ. The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 2004;103:179-201
6. Sugo S, Minamino N, Shoji H, et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 1994;203:719-726
7. Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech 2002;57:3-13
8. Parkes DG, May CN. Direct cardiac and vascular actions of adrenomedullin in conscious sheep. Br J Pharmacol 1997;120: 1179-1185
9. Niu P, Shindo T, Iwata H, et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation 2004;109:1789-1794
10. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101:498-503
11. Mart́inez A, Zudaire E, Portal-Ńunez S, et al. Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Res 2004;64:6489-6494
12. Rold́ os V, Mart́in-Santamaŕia S, Juli ́an M, et al. Small-molecule negative modulators of adrenomedullin: design, synthesis, and 3D-QSAR study. ChemMedChem 2008;3: 1345-1355
13. Robinson SD, Aitken JF, Bailey RJ, Poyner DR, Hay DL. Novel peptide antagonists of adrenomedullin and calcitonin generelated peptide receptors: identification, pharmacological characterization, and interactions with position 74 in receptor activity-modifying protein 1/3. J Pharmacol Exp Ther 2009;331:513-521
14. Deville JL, Salas S, Figarella-Branger D, Ouafik L, Daniel L. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets 2010;14:1059-1072
15. Garćia MA, Mart́in-Santamaŕia S, de Pascual-Teresa B, Ramos A, Juli ́an M, Mart́inez A. Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets 2006;10:303-317
16. Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of mid-regional proadrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010;56:125-133
17. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-1829
18. Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011;58:1057-1067
19. Elmas E, Lang S, Dempfle CE, et al. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int J Cardiol 2008;128:107-111
20. Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013;56:943-950
21. Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med 2013;31:215-221
22. Brouwers FP, de Boer RA, van der Harst P, et al. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart 2012;98: 1348-1353
23. Maier C, Clodi M, Neuhold S, et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009;32:1890-1895
24. Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012;33:2197-2205
25. von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484-491
26. Wild PS, Schnabel RB, Lubos E, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem 2012;58: 226-236
27. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Rischen RO, Meyboom-de Jong B. Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. Neth J Med 2005;63:103-110
28. Lutgers HL, Gerrits EG, Graaff R, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009;52: 789-797
29. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med 2 April 2013 [Epub ahead of print]
30. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109-120
31. Masson S, Latini R, Carbonieri E, et al.; GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12: 338-347
32. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008;54:17-23